SCHEDULE 13D/A 0001773187 XXXXXXXX LIVE 4 Common Stock, par value $0.001 per share 03/25/2025 false 0001160308 805111101 Savara Inc.

1717 Langhorne Newtown Road Suite 300 Langhorne PA 19047

Bain Capital Life Sciences In. 617-516-2000 200 Clarendon Street Boston MA 02116 0001773187 N Bain Capital Life Sciences Fund II, L.P. WC N E9 0 17600621 0 17600621 17600621 N 9.99 PN 0001702921 N BCIP Life Sciences Associates, LP WC N DE 0 17600621 0 17600621 17600621 N 9.99 PN 0001818893 N BCLS II Investco, LP WC N DE 0 17600621 0 17600621 17600621 N 9.99 PN Common Stock, par value $0.001 per share Savara Inc. 1717 Langhorne Newtown Road Suite 300 Langhorne PA 19047 This Amendment No. 4 to Schedule 13D relates to the Common Stock of Savara Inc. and amends the initial statement on Schedule 13D filed by the Reporting Persons on December 30, 2019, as amended on March 17, 2021, July 19, 2023 and April 12, 2024 (the "Initial Statement" and, as further amended by this Amendment No. 4, the "Schedule 13D"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Initial Statement. The information set forth in Items 2, 3 and 4 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5. As of the date hereof, (i) BCLS II directly holds 6,162,631 shares of Common Stock and Pre-Funded Warrants to purchase 18,533,412 shares of Common Stock, (ii) BCIPLS holds 750,577 shares of Common Stock and Pre-Funded Warrants to purchase 2,257,276 shares of Common Stock and (iii) BCLS II Investco holds 7,138,144 shares of Common Stock and Pre-Funded Warrants to purchase 5,666,667 shares of Common Stock. As a result of the Beneficial Ownership Blocker, the Reporting Persons are precluded from exercising Pre-Funded Warrants into shares of Common Stock to the extent that the Reporting Persons would, after such exercise, collectively beneficially own in excess of 9.99% of the outstanding Common Stock of the Issuer. Accordingly, pursuant to Rule 13d-3 of the Act and the relationships described in Item 2 of this Schedule 13D, the Reporting Persons may be deemed to collectively beneficially own 9.99% of the outstanding Common Stock of the Issuer, representing 17,600,621 shares of Common Stock as of the date hereof. The calculation of the beneficial ownership of the Reporting Persons is based on (i) 172,633,140 shares of Common Stock issued and outstanding as of March 27, 2025, as reported by the Issuer in its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025, and (ii) 3,549,269 shares of Common Stock to be issued upon the exercise of Pre-Funded Warrants held by the Reporting Persons, which reflects the Beneficial Ownership Blocker. See Item 5(a) hereof. Exhibit J to this Schedule 13D sets forth the transactions in the Common Stock of the Issuer effected by the Reporting Persons during the past sixty days, and is incorporated by reference into this Item 5(c). Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5. Not applicable. Item 7 of the Initial Statement is hereby amended and supplemented to add the following: Exhibit J Item 5(c) - Transactions effected by the Reporting Persons during the past sixty days Bain Capital Life Sciences Fund II, L.P. /s/ Ricky Sun 03/27/2025 BCIP Life Sciences Associates, LP /s/ Ricky Sun 03/27/2025 BCLS II Investco, LP /s/ Ricky Sun 03/27/2025